Archive: February 2023

The Emerging Use of Chemotherapy-Free Regimens in Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

Abstract: Before the development of tyrosine kinase inhibitors (TKIs), the outcome of patients with a diagnosis of Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia was dismal. Combinations […]

A Review of Essential Thrombocythemia and Its Complications

Abstract: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by an increased platelet count in the peripheral blood and excessive megakaryopoiesis in the bone marrow. […]

Addressing Cardiovascular Complications of BTK Inhibitors

H&O  What are the specific cardiovascular complications that are associated with Bruton tyrosine kinase (BTK) inhibitors? JM  Many cancer drugs have adverse effects on the heart […]

Noncovalent BTK Inhibitors in B-Cell Lymphoma

H&O  What are the limitations of standard (covalent) BTK inhibitors in B-cell malignancies? CC  The 2 major limitations of covalent Bruton’s tyrosine kinase (BTK) inhibitors are […]

New Staging Systems in Nonmetastatic Prostate Cancer

H&O How is prognosis typically estimated in nonmetastatic prostate cancer? FF We typically estimate prognosis with a variety of tools, including the Gleason score; levels of […]

Letter From the Editor: Too Much?

As previously mentioned, I want to continue sharing some of the thought-provoking and relevant clinical scenarios that arise during my time on the inpatient lymphoma service.  […]

Back to Archive